HIV, Lenacapavir and Gilead

Promising results from an early-stage trial suggest that lenacapavir injections might offer long-lasting protection.
Your FREE insider update on the biggest news stories and investing trends, delivered midday TheChart of the Day belongs to ...
Gilead Sciences set aside $200 million for a potential settlement with federal prosecutors to resolve an investigation into ...
Gilead Sciences announced a significant milestone: the U.S. FDA accepted their New Drug Applications (NDAs) for lenacapavir ...
The drug, which works by blocking HIV from entering and multiplying in human cells, remained in the body for at least 56 ...
Gilead has reported results for a once-yearly intramuscular injection that show blood concentrations of lenacapavir exceeded ...
We recently published a list of Top 10 Stocks Wall Street is Discussing. In this article, we are going to take a look at ...
An annual jab to protect against HIV “shows potential”, according to an early study. Millions of people around the world are ...